Skip to main content
Equibles
PRME logo

PRME · Prime Medicine, Inc. · Metrics

Track PRME — free

Use PRME with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research PRME.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$3.70 -0.11 (-2.90%)
Russell 2000 member Rebalance outlook locked
Going-concern doubt — flagged Aug 6, 2026

Substantial doubt about the company's ability to continue as a going concern.

“As a result, we concluded that substantial doubt exists about our ability to continue as a going concern for 12 months from the date these condensed consolidated financial statements are issued.”
View the 10-Q filed Aug 6, 2026
Market Cap
$691.05M
Shares
181.38M
Volume · Oct 21 2.44M Avg daily vol (3M) 3.47M

PRME metrics

75 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$3.81
Market cap
$691.05M

Price action

20 metrics
Price change (1W)
+21.7%
Price change (30D)
+7.6%
Price change (3M)
+23.3%
Price change (6M)
-3.8%
Price change (YTD)
+9.8%
Price change (1Y)
-31.8%
Trailing year
Price change (5Y)
—
52-week high
$5.59
52-week low
$2.70
Change from 52-week high
-31.8%
Change from 52-week low
+41.1%
Annualized volatility
87.9%
Annualized volatility (3M)
94.7%
Beta
2.3
RSI (14D)
56.4
Price vs SMA 50
+12.9%
Price vs SMA 200
+9.4%
Avg volume (3M)
3.47M
Relative volume
0.7
Average dollar volume
$11.62M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
181.38M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
149.2×
reciprocal yield 0.7%
P / book
17.4
reciprocal yield 5.8%
FCF yield
-22.7%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-27.2%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2025-11-12

Profitability

9 metrics
Gross margin
—
Operating margin
-4,498.1%
Trailing 12 months
Net margin
-4,342.4%
Gross profit (TTM)
—
Operating profit (TTM)
−$196.52M
Net income (TTM)
−$187.89M
Trailing 12 months
Diluted EPS (TTM)
$-1.06
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$0.03
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-1.15
EBITDA per diluted share (TTM)
$-1.10
Net income per diluted share (TTM)
$-1.10
Operating cash flow per diluted share (TTM)
$-0.91
Free cash flow per diluted share (TTM)
$-0.91
Capital expenditures per diluted share (TTM)
$0.00
R&D per diluted share (TTM)
$0.85
Stock compensation per diluted share (TTM)
$0.16
Book value per share
$0.67

Growth

11 metrics
Revenue growth YoY
-61.6%
Year over year
Net income growth YoY
—
Revenue (TTM)
$4.63M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+37.2%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
-2.3%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-472.0%
Return on assets
-75.4%
Debt / equity
—
Current ratio
3.1
EBITDA (TTM)
−$189.12M
Free cash flow (TTM)
−$156.85M
Quick ratio
3.1
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$47.45M
Latest balance sheet
Cash & equivalents
$47.45M
Total assets
$249.04M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$156.05M
Capital expenditures (TTM)
$797,000
R&D (TTM)
$146.20M
SG&A (TTM)
—
Stock compensation (TTM)
$26.77M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
188
13F filer change QoQ
-5
Institutional ownership
59.4%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
19.2%
Private-fund adviser ownership
17.4%
Active holders' share change QoQ
+5.4%
Holder tenure
10.6
Price vs estimated holder cost
-48.6%

Ownership (registered funds)

1 metrics
Index-fund ownership
11.1%

Short interest

3 metrics
Short interest
17.7%
Latest settlement · 8.5 days to cover
Days to cover
8.5d
Short-squeeze score
86 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1894562 CUSIP 74168J101 13F (30d) 16 filings 16 filers Visit website Investor relations